Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Condition(s):Head and Neck CancerLast Updated:November 14, 2023Not yet recruiting
Include Studies Not Open or Pending
Condition(s):Head and Neck CancerLast Updated:November 14, 2023Not yet recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:November 8, 2023Recruiting
Condition(s):Dermatomyositis; PolymyositisLast Updated:February 20, 2024Recruiting
Condition(s):Colorectal CancerLast Updated:March 27, 2024Recruiting
Condition(s):Metastatic or Locally Advanced Unresectable Solid TumorsLast Updated:March 12, 2024Recruiting
Condition(s):Head and Neck CancerLast Updated:March 6, 2024Recruiting
Condition(s):CancerLast Updated:February 20, 2024Recruiting
Condition(s):Locally Advanced or Metastatic Urothelial CarcinomaLast Updated:February 6, 2024Recruiting
Condition(s):Systemic Lupus ErythematosusLast Updated:March 6, 2024Recruiting
Condition(s):Central Nervous System TumorsLast Updated:March 12, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.